# Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome

> **NCT04366063** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Royan Institute** · enrollment: 60 (estimated)

## Conditions studied

- Covid-19

## Interventions

- **BIOLOGICAL:** Cell therapy protocol 1
- **BIOLOGICAL:** Cell therapy protocol 2

## Key facts

- **NCT ID:** NCT04366063
- **Lead sponsor:** Royan Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-05
- **Primary completion:** 2020-06-06
- **Final completion:** 2020-12-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-04-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04366063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04366063, "Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04366063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*